The Question Nobody Answers in the Consulting Room
A missed miscarriage is discovered on a scan, not felt. The heart that was supposed to be beating is not, the sac is there and empty, or the embryo stopped at seven weeks and the body has not yet noticed. A biochemical pregnancy is earlier still: a positive test, a rising hormone, and then a period that arrives a week late. Both leave a couple with the same question, and it is rarely answered in the ten minutes the follow-up appointment allows: what should we check before we try again.
The question gets answered badly in two opposite ways. One clinic says there is nothing to do, it was bad luck, go home and try — which is correct for most single losses and unbearable for anyone who has already had two. Another offers a folder of thirty tests, because tests feel like action. Neither is a plan. What a couple actually needs is a sequence: what a first loss justifies, what a second changes, and which findings would actually alter what happens in the next pregnancy.
Two facts frame everything below. The first is that early pregnancy loss is common — roughly one in five confirmed pregnancies, and considerably more if very early biochemical losses are counted. The second is that the cause is chromosomal in about half of cases, most often a numerical abnormality that arose in that embryo and will not recur.
That second fact is why the single most informative test after a loss is often the one nobody orders: the chromosomes of the pregnancy tissue itself. It answers "why did this one stop". Every other test on this page answers a different question — "is there something in us that keeps this from working" — and the two questions should not be mixed.
One Loss and Three Losses Are Not the Same Question
After a single loss, with no other history, the probability that a couple has an underlying condition is low, and the probability that a full workup will produce a false lead is not. This is why most guidelines do not recommend blanket investigation after one, and why a clinician who says "wait and try again" is not being dismissive — they are quoting the evidence.
What a single loss does justify is a basic screen: the cheap, high-yield checks that would be embarrassing to miss, plus — reasonably — the first layer of immune testing for anyone whose anxiety will not survive a year of waiting. In practice most couples in that position choose to do the basic panel and skip the rest. That is a defensible choice, and it is the one AMCARE's preconception team usually discusses first.
Two or more losses changes the arithmetic completely. Recurrent pregnancy loss is a defined condition with defined causes, and the workup becomes systematic rather than selective: chromosomes for both partners, an extended immune and thrombophilia panel, uterine assessment, and a review of every previous loss for gestation, tissue testing and circumstance.
The definition matters more than it sounds, because it determines who gets investigated. Two consecutive clinical losses now meet the threshold in most guidance; a biochemical pregnancy counts as a loss in some frameworks and not others. Couples who miscarry early and often are routinely told they "do not qualify" — and whether that is right depends on which definition the clinic is using. It is a fair question to ask.
The Woman's Basic Screen
Three systems, examined in the same cycle if possible, because the point is to look at the environment an embryo would be entering.
Endocrine. A full sex-hormone panel, a complete thyroid assessment including antibodies, prolactin, fasting glucose and insulin. The targets are the conditions that quietly disturb early implantation and early placental development: thyroid dysfunction, polycystic ovary syndrome, insulin resistance, hyperprolactinaemia. Thyroid deserves particular attention because the association with loss is well documented and the treatment is cheap.
Uterine anatomy. Transvaginal ultrasound first, and hysteroscopy where the ultrasound is ambiguous or a previous loss was late enough to suggest a structural contributor. The findings that matter are the ones that change the cavity an embryo has to implant into: septate uterus, adhesions, polyps, submucosal fibroids.
Infection. The TORCH panel — toxoplasmosis, rubella, cytomegalovirus, herpes simplex and the related group — is a crude instrument and a poor predictor of loss in most cases, but it identifies the occasional active infection that matters and establishes immunity status before pregnancy, which has practical value of its own.
The Immune Layer, Which Is Where the Real Decisions Are
Immune and thrombotic causes are the part of the workup that changes management, and also the part most often ordered without a plan for what the result will mean. The list is best understood in two tiers.
After one loss: anticardiolipin antibodies, anti-beta-2-glycoprotein-1 antibodies, lupus anticoagulant, and thyroid autoantibodies. These four are inexpensive, and a positive result in the phospholipid group is the one finding on this page that leads to a well-evidenced treatment — low-dose aspirin and prophylactic heparin in the next pregnancy, for confirmed antiphospholipid syndrome.
After two or more losses: the above, plus karyotyping of both partners, an extended antiphospholipid panel, an antinuclear antibody profile, a thrombophilia screen, homocysteine, and 25-hydroxyvitamin D. The rationale is that recurrent loss has a small number of recognised causes and each has a corresponding test; the point of the panel is to rule them in or out, not to accumulate data.
Two cautions belong here rather than in a footnote. Antiphospholipid antibodies are diagnosed on persistent positivity — two positive results at least twelve weeks apart — not on a single reading, because transient positivity after infection or surgery is common and treating it exposes a pregnancy to anticoagulation for no reason. And the ANA profile frequently returns a low-titre positive in healthy people; a positive ANA without clinical features is not a diagnosis of autoimmune disease and should not by itself trigger immunosuppressive treatment.
The Man Is Half the Embryo
The single most common failure in the workup after pregnancy loss is that only one partner is investigated. Half the genetic material in a lost pregnancy came from the father, and a meaningful proportion of recurrent loss is associated with sperm that looks normal under a microscope and is not normal inside.
A complete semen analysis covers concentration, motility and morphology — the three numbers everyone quotes. What it does not cover is DNA integrity, which is why sperm DNA fragmentation index has moved from research tool to standard request in this specific context. A high fragmentation index is associated with early loss, and it is invisible on a routine semen analysis: the sperm swims properly and carries damaged DNA.
Two further tests belong in the recurrent-loss setting. Peripheral blood karyotyping of the male partner detects balanced translocations — a rearrangement that causes no symptoms in the carrier and produces non-viable embryos at a predictable rate. And a basic endocrine review, with genitourinary ultrasound where indicated, covers the treatable contributors on the male side.
There is a practical argument for doing this at the same time as the woman's panel rather than after it. Sequential investigation adds months to a process that already involves waiting, and the results only make sense together.
Five Tests That Get Skipped
These are the items that carry real information and are most often left out — sometimes because they are inconvenient, sometimes because they do not appear in the standard package a clinic has assembled.
1. Chromosomal testing of the pregnancy tissue. The only test that answers why this pregnancy stopped. It requires that tissue be collected and sent at the time of the loss; once that window closes it cannot be recovered. If a couple is undecided about testing, the tissue can be kept while they decide — a conversation worth having before a procedure, not after.
2. Thyroid autoantibodies. Anti-TPO and anti-thyroglobulin positivity is associated with increased loss risk, including in women whose thyroid hormone levels are normal. It is a cheap addition to a thyroid panel and frequently omitted from it.
3. Antinuclear antibody profile. Beyond lupus, conditions such as Sjögren's syndrome and undifferentiated connective tissue disease are associated with adverse pregnancy outcomes, and they announce themselves in this panel long before they produce classic symptoms.
4. Homocysteine. A functional readout of folate and B-vitamin metabolism, and an independent risk marker in recurrent loss. It is also actionable: elevated homocysteine is treatable with the right form of folate, which is why finding it changes something.
5. Sperm DNA fragmentation. Covered above and worth repeating, because it sits on the male side of a workup that is still, in most clinics, organised around the woman.
More Tests Is Not More Reassurance
There is a specific harm in an unlimited workup, and it is not financial. Every additional test carries a false-positive rate, and after a loss couples are unusually willing to accept an explanation. A borderline antibody titre, a heterozygous variant in a thrombophilia panel, a mildly raised homocysteine — each of these can produce a treatment plan that involves daily injections, months of medication and a changed birth plan, on evidence that would not survive a careful reading.
The question to ask about any test on a list is the one that should precede all of them: if this comes back abnormal, what will we do differently, and is there evidence that doing it improves the chance of a live birth. Where the answer is clear — antiphospholipid syndrome, thyroid dysfunction, a balanced translocation, a septate uterus — the test earns its place. Where the answer is a referral to another test, it usually does not.
What couples are actually seeking after a loss is not a folder of results. It is a story that makes sense and a plan for the next attempt. A targeted panel produces both; a comprehensive one often produces neither, because it returns a set of minor abnormalities with no hierarchy attached.
Before the Next Attempt
The practical sequence that follows from all of this is unglamorous. Establish what happened: how many losses, at what gestation, and whether any tissue was tested. Then do the basic screen — endocrine, uterine, thyroid with antibodies, and the four first-line immune tests — and add the extended panel if this is the second or third loss rather than the first. Investigate the partner at the same time, not afterwards. Write down, before the results arrive, what each abnormal result would change.
Timing matters too. Most of these tests can be done in a single cycle, and nothing about them requires waiting six months before trying again — a belief that costs couples time they did not need to lose. The exceptions are specific: treatment for a confirmed thrombophilia or thyroid disorder should be in place before conception, not started after a positive test.
For couples travelling to Beijing for this, the practical questions are whether the full panel can be completed within one cycle and one visit, whether results and reports will be issued in English, and whether previous losses were documented well enough to be reviewed. AMCARE's obstetrics center runs preconception and recurrent-loss assessment as a coordinated pathway with the reproductive medicine and laboratory teams, and the international patient team can confirm the schedule before travel.
This article describes general principles of assessment after early pregnancy loss and does not replace individual medical advice. Which tests are appropriate depends on the number and timing of previous losses, past results, age and other history; some of the tests described require specific timing within the cycle or within the loss itself.
Reviewed by
Dr Fang Fang is lead physician for preconception care at the AMCARE obstetrics center in Beijing. She previously practised at the Beijing Dongcheng District Maternal and Child Health Hospital and holds a master's degree in obstetrics and gynaecology from Peking Union Medical College. She has more than twenty years of clinical experience in obstetrics and gynaecology and is also a registered dietitian.
Her clinical work covers preconception health assessment, optimisation of the pre-pregnancy environment, and systematic investigation of reproductive, endocrine and metabolic factors affecting conception — including ovulation monitoring, timing of conception, and lifestyle adjustment for older couples, polycystic ovary syndrome and thyroid disorders. She also works in perinatal care and the management of high-risk pregnancy.